In vitro and in vivo evaluation of anti-inflammatory agents using nanoengineered alginate carriers: Towards localized implant inflammation suppression-Reference-Cited by-同舟云学术

In vitro and in vivo evaluation of anti-inflammatory agents using nanoengineered alginate carriers: Towards localized implant inflammation suppression

Published:2011-01 Issue:1-2 Volume:403 Page:268-275
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Jayant Rahul Dev,McShane Michael J.,Srivastava Rohit

Funder

Board of Research in Nuclear Sciences BARC

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference38 articles.

1. Biosensors for in-vivo glucose measurement: can we cross the experimental stage;Abel;Biosens. Bioelectron.,2002

2. Biological responses to materials;Anderson;Annu. Rev. Mater. Res.,2001

3. Enzymatic fluorescent microsphere glucose sensors: evaluation of response under dynamic conditions;Brown;Diabetes Technol. Ther.,2006

4. Real-time continuous glucose monitoring;Buckingham;Curr. Opin. Endocrinol. Diabetes Obes.,2007

5. Glucose sensors based on microcapsules containing an orange/red competitive binding resonance energy transfer assay;Chinnayelka;Diabetes Technol. Ther.,2006

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-biofouling strategies for implantable biosensors of continuous glucose monitoring systems;Frontiers of Chemical Science and Engineering;2023-08-30

2. PLLA Coating of Active Implants for Dual Drug Release;Molecules;2022-02-19

3. Design and development of advanced glucose biosensors via tuned interactions between marine polysaccharides and diagnostic elements – A survey;Sensors International;2022

4. Polymeric Composite Matrix with High Biobased Content as Pharmaceutically Relevant Molecular Encapsulation and Release Platform;ACS Applied Materials & Interfaces;2021-08-23

5. Circumventing immune rejection and foreign body response to therapeutics of type 1 diabetes;Immunomodulatory Biomaterials;2021